Bernstein Maintains Natera(NTRA.US) With Buy Rating, Raises Target Price to $200
Positive Outlook for Natera: Buy Rating Driven by Strong Revenue Performance and Strategic Developments
Craig-Hallum Maintains Natera(NTRA.US) With Buy Rating, Raises Target Price to $174
Craig-Hallum Sticks to Their Buy Rating for Natera (NTRA)
Natera Is Maintained at Buy by Canaccord Genuity
Natera Analyst Ratings
CCORF Maintains Natera(NTRA.US) With Buy Rating, Raises Target Price to $180
Analysts Offer Insights on Healthcare Companies: Jazz Pharmaceuticals (JAZZ), Natera (NTRA) and Neumora Therapeutics, Inc. (NMRA)
TD Cowen Maintains Natera(NTRA.US) With Buy Rating, Raises Target Price to $195
Natera (NTRA) Receives a Buy From TD Cowen
Natera Is Maintained at Overweight by JP Morgan
Natera Analyst Ratings
J.P. Morgan Maintains Natera(NTRA.US) With Buy Rating, Raises Target Price to $200
Piper Sandler Maintains Natera(NTRA.US) With Buy Rating, Maintains Target Price $200
Piper Sandler Sticks to Their Buy Rating for Natera (NTRA)
UBS Maintains Natera(NTRA.US) With Buy Rating, Raises Target Price to $209
UBS Adjusts Price Target on Natera to $209 From $145, Maintains Buy Rating
Natera Is Maintained at Overweight by Piper Sandler
Natera Analyst Ratings
Natera Analyst Ratings